Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 6/20 | 0.54 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7218772 | 0.89 | CRHR1 (0.58) | CRHR1 | |
| SCHEMBL7218775 | 0.89 | CRHR1 (0.58) | CRHR1 | |
| SCHEMBL7217253 | 0.80 | CRHR1 (0.54) | CRHR1 | |
| SCHEMBL7217257 | 0.80 | CRHR1 (0.54) | CRHR1 | |
| SCHEMBL5866990 | 0.74 | CRHR1 (0.66) | CRHR1 | |
| SCHEMBL5867008 | 0.74 | CRHR1 (0.47) | CRHR1HCAR3 | |
| SCHEMBL5866781 | 0.73 | CRHR1 (0.48) | CRHR1 | |
| SCHEMBL7945728 | 0.72 | CRHR1 (0.37) | CRHR1KDM4E | |
| SCHEMBL7224230 | 0.71 | CRHR1 (0.85) | CRHR1 | |
| SCHEMBL7224264 | 0.71 | CRHR1 (1.00) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6525056-B2 | A fused nitrogen containing heterocyclic compound useful for treating psychiatric and neurological disorders, anxiety, post-traumatic stress, supranuclear palsy, feeding, immunological, cardiovascular and hypersensitivity disorders | BRISTOL-MYERS SQUIBB COMPANY | 2003-02-25 | — | — | US | disclosed |
| US-6448261-B1 | CORTICOTROPIN RELEASING FACTOR ANTAGONISTS; TREATING ANXIETY, DEPRESSION, AND OTHER PSYCHIATRIC AND NEUROLOGICAL DISORDERS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-09-10 | — | — | US | disclosed |
| EP-1012151-B1 | HETEROCYCLYL-SUBSTITUTED RING-FUSED PYRIDINES AND PYRIMIDINES AS CORTICOTROPIN RELEASING HORMONE (CRH) ANTAGONISTS, USEFUL FOR TREATING CNS AND STRESS-RELATED DISORDERS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2002-08-07 | — | — | EP | disclosed |
| EP-0935601-A4 | ARYLAMINO FUSED PYRIDINES AND PYRIMIDINES | DU PONT PHARM CO (US) | 2002-08-07 | — | — | EP | disclosed |
| US-20010025042-A1 | Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (CRH) antagonists, useful for treating cns and stress-related disorders | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2001-09-27 | — | — | US | disclosed |
| US-6245769-B1 | Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone(CRH) antagonists, useful for treating CNS and stress-related disorders | DUPONT PHARMACEUTICALS COMPANY | 2001-06-12 | — | — | US | disclosed |
| US-6107300-A | CORTICOTROPIN RELEASING FACTOR ANTAGONIST; PSYCHOLOGICAL DISORDERS | DUPONT PHARMACEUTICALS (US) | 2000-08-22 | — | — | US | disclosed |
| EP-0935601-A2 | ARYLAMINO FUSED PYRIDINES AND PYRIMIDINES | Du Pont Pharmaceuticals Company (US) | 1999-08-18 | — | — | EP | disclosed |
| WO-1997035539-A2 | ARYLAMINO FUSED PYRIDINES AND PYRIMIDINES | DU PONT PHARMACEUTICALS COMPANY (US) | 1997-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010025042-A1 | Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (CRH) antagonists, useful for treating cns and stress-related disorders | CRH, CRHR1, CRHR2 | CRHR1 2/4885HCAR3 718/4885KDM4E 4544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.